Trevena inc (TRVN) - News Archive

Showing 5 of 5 results.

Trevena Inc. Faces Nasdaq Delisting Amid Struggles to Regain Compliance

Chesterbrook, Pa. Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) disorders, has recently received a discouraging notice from the...

Oct 4, 2024 • Major Pharmaceutical Preparations Industry Stock Market Announcement

Trevena Initiates Reverse Stock Split to Drive Compliance and Encourage Growth,

Trevena Announces Reverse Stock Split: A Strategic Move Towards Compliance and GrowthCHESTERBROOK, Pa., Aug. 08, 2024 - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company specializing in the development and comme...

Aug 8, 2024 • Major Pharmaceutical Preparations Industry Shares

Trevena Secures $2M Non-Dilutive Financing Tranche and Exhibits Lower Liabilities, Paving Way for Development Milestones

Trevena Inc., a renowned biopharmaceutical company focused on developing innovative therapies, has recently announced a significant financial milestone as part of its ongoing efforts to advance its lead product, OLINVYK...

Jul 8, 2024 • Major Pharmaceutical Preparations Industry Financing Agreement

Trevena Inc Closes $1946 Million Private Placement Offering and Sees Improved Leverage Ratio Performance

Trevena Inc. Closes $1.946 Million Private Placement Offering and Sees Improved Leverage Ratio PerformanceCHESTERBROOK, Pa., Dec. 28, 2023 - Trevena Inc., a biopharmaceutical company dedicated to developing and commerci...

Dec 28, 2023 Financing Agreement

Advancing Burn Care: Investigator-Initiated Study Explores the Use of OLINVYK in Acute Burn Injuries

Trevena Announces Acceptance of Examining the Use of OLINVYK in Patients with Acute Burn Injuries Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Me...

Nov 30, 2023 Clinical Study